Direct antiviral therapy in patients with HCV: evidence from Saudi Arabia
Published in Microbiology, Genetics & Genomics, and Public Health
It is well established that the primary goal of treatment for chronic hepatitis C is to achieve a sustained virologic response (SVR)—the absence of detectable hepatitis C virus RNA for at least 12 weeks (SVR12) or 24 weeks (SVR24)—and to reduce overall mortality and liver-related complications, including end-stage liver disease, hepatocellular carcinoma, and morbidity and mortality associated with extrahepatic manifestations of chronic hepatitis C virus infection. Achieving an SVR significantly reduces hepatic and extrahepatic complications associated with HCV, improves quality of life and prevents HCV transmission.
According to the latest data for 2016, approximately 0.5% of the Saudi population was actively infected with hepatitis C, of which approximately 20% had been previously diagnosed, and approximately 50% of these patients had been treated. Furthermore, 50% of treated hepatitis C patients were cured with standard therapy using pegylated interferon and ribavirin. An additional 5,000 people were treated with new direct-acting antiviral (DAA) drugs, with a cure rate of >90%.
In this study, we aimed to evaluate the real-world outcomes of treating Saudi patients infected with HCV with DAAs as part of a national campaign to eliminate this disease in Saudi Arabia. Unlike previous reports, we aimed to provide complete follow-up data (SVR12 and SVR24) and identify proportion of unspecified genotypes, which would contribute to understanding current diagnostic and therapeutic options in clinical practice.
The study included a sample of 144 Saudi patients infected with hepatitis C virus who were treated as outpatients and received DAA therapy between January 2016 and December 2023. All patients completed therapy and achieved SVR at 12 and 24 weeks. We attributed this to strict adherence monitoring, free therapy under the national program, and comprehensive follow-up protocols that minimized treatment discontinuations.
The most common genotype was GT4 (38.9%), followed by GT1(a and b) (20.1%). We also referenced previous studies describing the regional distribution of HCV genotypes and thus hypothesized that GT4 is the dominant genotype in Middle Eastern countries. In addition to examining known HCV genotypes, we also discovered a novel pattern in the Saudi population: of n = 144 patients, n = 42 (29.2%) had an unknown genotype. To our knowledge, this is the first study to report such a large proportion of cases with an unknown genotype. However, since this study was retrospective, we proposed further study of this genotype in prospective genetic studies.
Another finding that requires further study in prospective studies was that despite successful completion of the treatment course with 100% sustained virologic response, resulting in a significant reduction in mean liver enzyme levels—alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP)—the level of conjugated bilirubin did not change.
With the World Health Organization projecting a 90% reduction in new hepatitis cases and a 65% reduction in deaths between 2016 and 2030, these emerging data from Saudi Arabia are worth considering. We believe that new studies should consider a thorough investigation of unknown genotypes and examination of associated risk factors that may lead to liver fibrosis, as well as the association of age and gender with HCV genotypes with the inclusion of a larger population. Moreover, research based on these data will provide a deeper understanding of the effectiveness and durability of treatments, which may not only improve patient care but also inform health policy and recommendations, ultimately leading to improved health outcomes.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Infectious disease management in infants and children
BMC Infectious Diseases invites submissions for a Collection on Infectious diseases in infants and children.
Infectious diseases in infants and children represent a significant burden on healthcare systems globally, often leading to serious complications, long-term health issues, and even mortality. This Collection aims to explore the diverse range of infectious diseases that specifically affect the pediatric population, including but not limited to respiratory infections, gastrointestinal infections, and vaccine-preventable diseases. Understanding the unique immune responses and vulnerabilities of young children is crucial for developing effective prevention and treatment strategies tailored to their needs.
The continued research into pediatric infectious diseases is vital for several reasons. Advances in immunization have significantly reduced the incidence of many vaccine-preventable diseases; however, challenges remain, particularly with the emergence of antimicrobial resistance and the resurgence of certain infections. Furthermore, the COVID-19 pandemic has underscored the importance of infection control measures in childcare, preschool, and school settings and highlighted the need for ongoing surveillance of childhood diseases. This area of research promises to contribute to improved health outcomes for infants and children worldwide.
With sustained research efforts, we can anticipate significant advances in the future, including the development of novel vaccines, improved diagnostics, and tailored treatment protocols. Continued exploration of the epidemiology of childhood diseases will further enhance our understanding of transmission dynamics and inform public health interventions.
We invite pediatricians, infectious disease specialists, public health professionals, immunologists, epidemiologists, and researchers in related fields to contribute original research articles on topics including but not limited to:
- Pediatric infectious diseases and their management
- Early childhood immunity and its implications
- Epidemiology of respiratory infections in children
- Antimicrobial resistance trends in pediatric settings
- Infection control in childcare, preschool, and school settings
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 30, 2026
Hepatitis virus infections and treatment
BMC Infectious Diseases invites submissions for a Collection on Hepatitis virus infections and treatment.
Hepatitis virus infections—including types A, B, C, D, and E—remain a significant global public health concern, collectively affecting hundreds of millions of people and contributing to a wide spectrum of liver-related diseases. These range from acute hepatitis and chronic liver inflammation to cirrhosis and hepatocellular carcinoma. Each hepatitis virus presents unique challenges in terms of transmission, disease progression, and treatment, with varying impacts across different regions and populations.
While hepatitis C has seen transformative progress with the development of Direct-Acting Antivirals (DAAs), hepatitis B continues to pose challenges due to its chronic nature and the need for lifelong management. Hepatitis A and E, typically transmitted via the fecal-oral route, are preventable through improved sanitation and vaccination, yet outbreaks still occur in resource-limited settings. Hepatitis D, which only occurs in conjunction with hepatitis B, adds complexity to diagnosis and treatment strategies.
Recent advances in diagnostics, therapeutics, and public health interventions have improved outcomes for many affected individuals. However, disparities in access to care, limited awareness, and gaps in screening and vaccination programs hinder global efforts to eliminate viral hepatitis as a public health threat. Continued research is essential to develop more effective prevention strategies, enhance treatment protocols, and understand the epidemiological and clinical nuances of each hepatitis virus. This Collection welcomes research that explores:
- Innovations in antiviral therapies across hepatitis types
- Epidemiology and transmission dynamics of hepatitis A–E
- Vaccine development and implementation strategies
- Novel diagnostic tools for acute and chronic hepatitis
- Public health approaches to hepatitis prevention and control
- Clinical implications of co-infections (e.g., HBV/HDV)
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 20, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in